港股異動 | 友邦保險漲逾2% 第三季新業務價值同比上升1%
格隆匯10月28日丨友邦保險(1299.HK)現報76.7港元,漲2.61%,帶動恆指漲超60點,暫成交7.8億港元,最新總市值9272億港元。友邦今晨公佈第三季業績稱,期內新業務價值同比上升1%至9.8億美元;不計入香港業務,新業務價值同比增長14%;年化新保費同比減少8%至14.44億美元;新業務價值利潤率增加6個百分點至67%;總加權保費收入同比上升8%至81.68億美元。今年前三季新業務價值同比增長13%至32.55億美元。大摩今日發報告表示,友邦公佈今年第三季新業務價值按年升1%,符合市場預期。並指其在內地業務仍然強勁,屬公司增長最快的市場。維持“增持”評級及目標價92港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.